Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and ...

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly’s latest weight-loss shot helped patients lose as much as 29 per cent of their body weight in trials, giving ...

Eli Lilly (LLY) stock rises as analysts cheer Phase 3 trial data for the company's next-gen weight loss therapy, retatrutide.

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla ...

Some patients dropped out of the trial early because they had lost so much weight.

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial. The company said the drug delivered weight loss of up ...

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...